4 results match your criteria: "The Harvard Medical School Center for Bioethics.[Affiliation]"
Performance-Linked Reimbursement and the Uncertainty of Novel Drugs.
Circ Cardiovasc Qual Outcomes
January 2022
Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, and the Harvard Medical School Center for Bioethics, Boston, MA.
Justice in CRISPR/Cas9 Research and Clinical Applications.
AMA J Ethics
September 2018
A pediatric oncologist at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an ethicist at Boston Children's Hospital, and on the teaching faculty at the Harvard Medical School Center for Bioethics in Boston.
CRISPR/Cas9 is a rapidly developing gene editing technology that will soon have many clinical applications. As with many other new technologies, somatic gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies by historically disenfranchised racial and ethnic minorities. We describe justice concerns related to CRISPR/Cas9, including its potential impact on historically mistreated populations through underrepresentation of minorities in genomic databases and the potential for disparate access to somatic gene therapies when they become clinically available.
View Article and Find Full Text PDFRevised 'Common Rule' Shapes Protections For Research Participants.
Health Aff (Millwood)
May 2017
Barbara E. Bierer is faculty co-director of the Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center); director of the Regulatory Foundations, Ethics and Law Program, Harvard Catalyst; and a professor of Medicine at Brigham and Women's Hospital and Harvard Medical School, in Boston, Massachusetts. Mark Barnes is a partner at Ropes and Gray LLP, a visiting lecturer at Yale Law School, and faculty co-director of the MRCT Center. Holly Fernandez Lynch is executive director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, and faculty in the Harvard Medical School Center for Bioethics.
Investigators and institutions have begun to prepare for new federal protections of study participants set to take effect in 2018.
View Article and Find Full Text PDF